middle.news
FDA Opens Potential Single-Trial Pathway for Neurizon’s ALS Therapy
9:57am on Tuesday 6th of October, 2026 AEDT
•
Biotechnology
Read Story
FDA Opens Potential Single-Trial Pathway for Neurizon’s ALS Therapy
9:57am on Tuesday 6th of October, 2026 AEDT
Key Points
FDA feedback identifies a potential traditional approval pathway for NUZ-001
HEALEY Regimen I could serve as the single registrational study for an NDA
Approval remains conditional on positive results and substantial evidence of effectiveness
Regimen I is fully enrolled, with topline results due in late Q2 2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE